Docstoc

Acute Coronary Syndrome Drug Pipeline Analysis

Document Sample
Acute Coronary Syndrome Drug Pipeline Analysis Powered By Docstoc
					Acute Coronary Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016

The Acute Coronary Syndrome Market is Estimated to Shrink at a Compound Annual
Growth Rate (CAGR) of 1% from 2009 to 2016

The global Acute Coronary Syndrome (ACS) market was valued at $1,021m in 2009 and
is forecast to decline by 1% annually for the next seven years to reach $949m in 2016.
This decline in market size is primarily due to the patent expirations of six branded drugs
which will subsequently allow the entry of generics.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Acute-Coronary-
Syndrome-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

At present the ACS market is competitive with six approved drugs. The dominant class of
drug is glycoprotein (GP) IIb/IIIa receptor antagonist. Plavix is an ADP mediated GP
IIb/IIIa receptor antagonist in combination with aspirin and dominates the market.
Lovenox which was approved in 2007 dominates the Percutaneous Coronary
Intervention (PCI) treatment segment of the ACS market. The heavy intracranial
bleeding and abdominal bleeding associated with high doses of these anti coagulants
leaves a significant area of unmet need for a new entrant.

Sanofi-Aventis, GlaxoSmithKline (GSK), and Bristol-Myers Squibb, are the leading
competitors in the global ACS market. The competitive landscape is moderately
populated with six products, three of which can be described as strong. This market is
characterized by moderate levels of off label usage.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Acute-Coronary-
Syndrome-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

Approximately 42 clinical studies were in different developmental stages in 2009.
Brilinta, Arixtra, and Apixaban, are the key products currently in the pipeline. Brilinta is a
me-too drug that is expected to be more efficacious than Plavix. Factor Xa inhibitors are
the dominate class of anti coagulants found in the later stages of the pipeline. The early
stages of the pipeline consist of novel molecules that potentially can induce disease
modification.

GlobalData, the industry analysis specialist, has released its latest research “Acute
Coronary Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016”. The report
provides key data, information and analysis on the global acute coronary syndrome
disease market. The report provides a comprehensive overview of the annualized
market data from 2001 to 2009, and forecasts for seven years to 2016. The report
provides coverage of the market landscape, market drivers and restraints, and an in-
depth pipeline analysis. The current competitive landscape is also analyzed and the
unmet need or commercial opportunity of the market is calculated. The pipeline analysis
covers molecules across all phases of clinical development and provides an overview of
the developing trends among pipeline molecules, as well as an insight into the most
promising pipeline drugs supplemented with key company profiles. By considering the
current competition in the market and the prospects of the pipeline molecules, the
resulting implications for the future market competition is also outlined.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Acute-Coronary-
Syndrome-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

Or visit our report store: http://www.globaldata.com/reportstore

				
DOCUMENT INFO
Shared By:
Stats:
views:25
posted:2/15/2010
language:English
pages:2
Description: The report provides key data, information and analysis on the global acute coronary syndrome disease market.